Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.46 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | GBA1 | P04062 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6407587 | 0.95 | OPRM1 (0.42) | OPRM1OPRD1HTR2AGBA1AGTR2 | |
| SCHEMBL3073767 | 0.87 | GBA1 (0.45) | OPRM1OPRD1HTR2AGBA1MEN1 | |
| SCHEMBL3085645 | 0.83 | PDPK1 (0.50) | OPRM1OPRD1HTR2AGBA1MEN1 | |
| SCHEMBL3075531 | 0.81 | OPRM1 (0.44) | OPRM1OPRD1HTR2AGBA1MEN1 | |
| SCHEMBL7046732 | 0.69 | PDPK1 (0.53) | GBA1SIGMAR1 | |
| SCHEMBL27672080 | 0.69 | S1PR5 (0.71) | OPRM1OPRD1HTR2AGBA1AGTR2 | |
| SCHEMBL3063424 | 0.68 | MEN1 (0.34) | MEN1KMT2A | |
| SCHEMBL11227003 | 0.66 | GBA1 (0.61) | OPRM1OPRD1GBA1SIGMAR1 | |
| SCHEMBL7003079 | 0.66 | SLC6A3 (0.61) | HTR2AGBA1KCNH2SIGMAR1 | |
| Hydrochloric Acid SCHEMBL28290331 | 0.65 | OPRM1 (0.51) | OPRM1OPRD1HTR2AGBA1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | claimed |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | SIRÈN MATTI (FI) | 2016-03-17 | — | — | US | disclosed |
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | BIONERIS AB | 2010-10-14 | — | — | US | disclosed |
| US-20090175924-A1 | COATED STENT | BIONERIS AB (SE) | 2009-07-09 | — | — | US | disclosed |
| EP-1390045-B1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF PHOSPHOROUS-CONTAINING RADICALS FOR THE TREATMENT OF RESTENOSIS | BIONERIS AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20050261756-A1 | Coated stent | BIONERIS AB (SE) | 2005-11-24 | — | — | US | disclosed |
| US-6949517-B1 | Method of treating inflammatory, tissue repair and infectious conditions | SIREN MATTI | 2005-09-27 | — | — | US | disclosed |
| EP-1545643-A1 | COATED STENT | Bioneris AB, (SE) | 2005-06-29 | — | — | EP | disclosed |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | BIONERIS AB (SE) | 2004-11-25 | — | — | US | disclosed |
| WO-2004022123-A1 | COATED STENT | BIONERIS AB (SE) | 2004-03-18 | — | — | WO | disclosed |
| EP-1390045-A1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF RADICALS FOR THE TREATMENT OF RESTENOSIS | Bioneris AB, c/o Ekonomikonsult Islinge KB (SE) | 2004-02-25 | — | — | EP | disclosed |
| EP-0910383-B1 | THE USE OF GROWTH FACTOR MODULATING COMPOUNDS | BIONERIS AB (SE) | 2003-10-15 | — | — | EP | disclosed |
| US-6632797-B2 | Administering to a mammal a cyclic compound (acyclic, carbocyclic or heterocyclic) substituted by at least three vicinal phosphorus containing radicals for treating angiogenesis in tumor conditions | SIREN MATTI (FI) | 2003-10-14 | — | — | US | disclosed |
| WO-2002096436-A1 | THE USE OF A COMPOUND WITH A NEGATIVELY CHARGED DOMAIN OF RADICALS FOR THE TREATMENT OF RESTENOSIS | BIONERIS AB (SE) | 2002-12-05 | — | — | WO | disclosed |
| EP-1216705-A2 | The use of growth factor modulation compounds substituted with three vicinal phosphorus containing radical in the manufacture of a medicament for tissue repair | PERSTORP AB (SE) | 2002-06-26 | — | — | EP | disclosed |
| US-20020065253-A1 | Use of growth factor modulating compounds | SIREN MATTI (FI) | 2002-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261682-A1 | Method and Means for the Treatment of Cachexia | PYGM, GYS1, CPT1B | OPRM1 53/4885OPRD1 103/4885HTR2A 2407/4885 |
| US-20020065253-A1 | Use of growth factor modulating compounds | HDGF, PGF, FGF2 | OPRM1 990/4885OPRD1 1988/4885HTR2A 1137/4885 |
| US-20160074421-A1 | METHOD FOR THE TREATMENT OF DISEASES CAUSED BY HAEMORRHAGIC VIRUSES AND COMPOUNDS FOR USE IN SAID TREATMENT | TTPA, LPO, HADHB | OPRM1 498/4885OPRD1 722/4885HTR2A 3912/4885 |
| US-20040235799-A1 | Use of a compound with a negatively charged domain of radicals for the treatment of restenosis | PCNA, OPRK1, OGFR | OPRM1 32/4885OPRD1 11/4885HTR2A 2575/4885 |
| US-20090175924-A1 | COATED STENT | PHOSPHO1, SOST, PLCB3 | OPRM1 68/4885OPRD1 28/4885HTR2A 2961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.